Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $50.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 51.93% from the company’s current price.
A number of other brokerages also recently commented on COLL. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.80.
Check Out Our Latest Analysis on Collegium Pharmaceutical
Collegium Pharmaceutical Stock Performance
Institutional Trading of Collegium Pharmaceutical
Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC raised its stake in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical during the third quarter worth $72,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Collegium Pharmaceutical by 61.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company’s stock valued at $239,000 after buying an additional 2,352 shares during the last quarter.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Articles
- Five stocks we like better than Collegium Pharmaceutical
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Short Selling: How to Short a Stock
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Transportation Stocks Investing
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.